Scribe Therapeutics Inc. Common Stock

Scribe Therapeutics Inc. is a clinical-stage biotechnology company focused on researching and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. Its pipeline includes STX-1150, a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200, a CRISPR-based gene editing program intended as a permanent solution for patients with elevated Lp(a); and STX-1400, designed to target and remove the transcriptional start site of the APOC3 gene to strongly reduce mRNA expression. The company uses CRISPR-based platforms including ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence, and XE, designed to support specific and efficient gene editing. Scribe Therapeutics was incorporated in 2017 and is headquartered in Alameda, California.

Biotech & Genomic Medicine▲

Scribe Therapeutics Reports Q2 2026 Results and Pipeline Progress

Scribe Therapeutics reported its second quarter 2026 financial results, highlighting the initiation of a first-in-human Phase 1 trial for STX-1150, an LDL-C lowering therapy, and the completion of an upsized initial public offering that raised approximately $155.5 million in aggregate gross proceeds. The company also secured over $25 million in grants from the California Institute for Regenerative Medicine to advance two other cardiometabolic programs. As of June 30, 2026, Scribe held $43.0 million in cash, cash equivalents, and marketable securities, which, combined with approximately $140.6 million in net proceeds from the July 2026 IPO and a concurrent private placement to Sanofi, is expected to fund operations into the first half of 2029. The company reported a net loss of $6.5 million for the quarter, compared to a net loss of $9.9 million in the same period last year.

SCTX ▲

Biotech & Genomic Medicine

GlobeNewswire·16dRead more →